Virologic failure of antiretroviral therapy (ART) may be explained by single nucleotide
polymorphisms (SNPs) in drug absorption and metabolism genes. Here, we characterized …

Summary Objectives Cytochrome P450 (CYP) enzyme polymorphisms seem to significantly
influence the variability of the responses to certain antiretroviral drugs and their toxicity …

Background: Antiretroviral therapy including HIV protease inhibitors and nonnucleoside
reverse transcriptase inhibitors can both inhibit and induce expression of cytochrome P450s …

Background Drug metabolism via the cytochrome P450 (CYP450) system has emerged as
an important determinant in the occurrence of several drug interactions (adverse drug …

Objective: CYP2B6 variation predicts pharmacokinetic characteristics of its substrates.
Consideration for underlying genetic structure is critical to protect against spurious …

Purpose CYP2B6 liver enzyme metabolizes the two non-nucleoside reverse transcriptase
inhibitors Efavirenz (EFV) and Nevirapine (NVP) used in the antiretroviral therapy (ART) …

Adverse reactions are the main cause of treatment discontinuation among HIV+ individuals.
Genes related to drug absorption, distribution, metabolism and excretion (ADME) influence …

Background Antiretroviral treatment is highly effective in enhancing HIV-positive patients'
survival and quality of life. Despite an increased tolerability in recent years, a substantial …

Background: The objective of this research was to identify the impact of genetic variants of P-
glycoprotein (ABCB1) and cytochrome P450 (CYP) on nelfinavir pharmacokinetics and …

Introduction: Variations in the human genome sequence sometimes play an important role in
pharmacokinetics and/or pharmacodynamics. Previous studies have demonstrated a high …